Bank of Montreal Can purchased a new position in shares of GSK plc (NYSE:GSK – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,477 shares of the pharmaceutical company’s stock, valued at approximately $302,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of GSK. Nemes Rush Group LLC acquired a new position in shares of GSK in the 2nd quarter valued at approximately $48,000. Perigon Wealth Management LLC raised its position in shares of GSK by 10.4% in the 2nd quarter. Perigon Wealth Management LLC now owns 8,764 shares of the pharmaceutical company’s stock valued at $312,000 after purchasing an additional 825 shares in the last quarter. Truist Financial Corp raised its position in shares of GSK by 6.1% in the 2nd quarter. Truist Financial Corp now owns 242,461 shares of the pharmaceutical company’s stock valued at $8,641,000 after purchasing an additional 13,991 shares in the last quarter. Farmers & Merchants Investments Inc. raised its position in shares of GSK by 233.0% in the 2nd quarter. Farmers & Merchants Investments Inc. now owns 3,573 shares of the pharmaceutical company’s stock valued at $127,000 after purchasing an additional 2,500 shares in the last quarter. Finally, BDO Wealth Advisors LLC raised its position in shares of GSK by 25.6% in the 2nd quarter. BDO Wealth Advisors LLC now owns 1,945 shares of the pharmaceutical company’s stock valued at $69,000 after purchasing an additional 396 shares in the last quarter. 13.53% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $1,553.75.
GSK Price Performance
Shares of NYSE GSK opened at $35.11 on Tuesday. GSK plc has a twelve month low of $33.17 and a twelve month high of $39.74. The company has a current ratio of 0.95, a quick ratio of 0.70 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $71.89 billion, a price-to-earnings ratio of 9.44, a price-to-earnings-growth ratio of 1.65 and a beta of 0.66. The business has a 50 day simple moving average of $36.05 and a 200-day simple moving average of $35.44.
GSK Cuts Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 17th will be issued a $0.3398 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.87%. GSK’s dividend payout ratio (DPR) is 35.48%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- How to Choose Top Rated Stocks
- The most upgraded stocks in November have two things in common
- How to Invest in the Entertainment Industry
- Monday.com rocked earnings like it’s the weekend
- 3 Monster Growth Stocks to Buy Now
- Plan to own one retailer? Make it this one
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.